Image Courtesy of BioVentrix
BioVentrix has received the renewal of the highest priority reimbursement in Germany for its transcatheter device for left ventricular remodeling after a heart attack.
The San Ramon, CA-based company said it has achieved NUB Status 1 designation from InEk, the German Institute for Hospital Remuneration for the Revivent TC TransCatheter Ventricular Enhancement System.
The NUB process enables participating German hospitals to receive full reimbursement plus a supplemental payment when utilizing groundbreaking medical technologies not listed in the existing German healthcare system. NUB Status 1 was only assigned to a handful of innovative technologies. This is the fourth consecutive year that the Revivent TC System has achieved this status in 100+ hospitals in Germany.
The Revivent TC System is used in the Less Invasive Ventricular Enhancement (LIVE) procedure, to exclude scar tissue on the left ventricle that has resulted from a heart attack, so the healthy portion of the heart can function more efficiently. Micro-anchors are implanted and designed to remodel the heart to a more normal shape and size and reduce wall stress, which has the potential to improve blood flow throughout the body.